{
    "root": "657f48b0-40b3-4a06-a244-741044b43d7d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KYBELLA",
    "value": "20241030",
    "ingredients": [
        {
            "name": "DEOXYCHOLIC ACID",
            "code": "005990WHZZ"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC",
            "code": "GR686LBA74"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        }
    ],
    "indications": "kybella® ( deoxycholic acid ) injection indicated improvement appearance moderate severe convexity fullness associated submental fat adults . limitations safe effective kybella treatment subcutaneous fat outside submental region established recommended .",
    "contraindications": "0.2 ml injections spaced 1 cm apart sites planned treatment area injected . ( 2.1 ) 50 injections 10 ml may injected single treatment . ( 2.1 ) 6 single treatments may administered intervals less 1-month apart . ( 2.1 ) general considerations injection technique injection . ( 2.2 , 2.3 )",
    "warningsAndPrecautions": "kybella ( deoxycholic acid ) injection , 10 mg/ml clear , colorless , sterile solution supplied 2 ml , single patient vials following dispensing pack : 4 vials , ndc 61168-101-04 store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . kybella unique hologram vial label . hologram , product call 1-800-678-1605. vial single patient . dilute mix kybella compounds . discard unused portion .",
    "adverseReactions": "kybella injection contraindicated presence infection injection sites .",
    "indications_original": "KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.\n                  \n                     Limitations of use\n                  \n                  The safe and effective use of KYBELLA for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.",
    "contraindications_original": "0.2 mL injections spaced 1 cm apart until all sites in the planned treatment area have been injected. ( 2.1 ) Up to 50 injections or 10 mL may be injected in a single treatment. ( 2.1 ) Up to 6 single treatments may be administered at intervals no less than 1-month apart. ( 2.1 ) See General Considerations for Administration and Injection Technique before injection. ( 2.2 , 2.3 )",
    "warningsAndPrecautions_original": "KYBELLA (deoxycholic acid) injection, 10 mg/mL is a clear, colorless, sterile solution supplied in 2 mL, single patient use vials in the following dispensing pack:\n                  4 vials, NDC 61168-101-04\n                  Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F)  [See USP Controlled Room Temperature].\n                  KYBELLA has a unique hologram on the vial label.  If you do not see a hologram, do not use the product and call 1-800-678-1605. \n                  Each vial is for a single patient use.  Do not dilute or mix KYBELLA with other compounds.  Discard unused portion.",
    "adverseReactions_original": "KYBELLA injection is contraindicated in the presence of infection at the injection sites."
}